



JC06 Rec'd PCT/PTO 06 SEP 2005

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission	14	Application Number	10/535,443
		Filing Date	May 19, 2005
		First Named Inventor	Gendreau
		Art Unit	
		Examiner Name	
		Attorney Docket Number	EX03-098C-US

### ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Document copies Return Receipt Postcard
<b>Remarks</b>		

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT


Firm	Exelixis, Inc.		
Signature			
Printed Name	Laleh Shayesteh		
Date	September 1, 2005	Reg. No.	47,937

### CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Signature			
Typed or printed name	Laleh Shayesteh	Date	September 1, 2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Gendreau *et al.*

Application No.: 10/535,443

Filed: May 19, 2005

For: FLJ10607 AS MODIFIER OF THE  
AXIN PATHWAY AND METHODS  
OF USE

Confirmation No.: 8809

Art Unit: Not Assigned

Examiner: Not Assigned

Attorney Docket No.: EX03-098C-US

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. §1.56, this Information Disclosure Statement is being submitted for the above-referenced application.


In accordance with 37 C.F.R. §1.97 (g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined by 37 C.F.R. §1.56 exists.

In accordance with 37 C.F.R. §1.97 (h), the disclosure contained herein is not intended to constitute an admission that any patent, publication, or other information referred to is "prior art" or "analogous art" for this invention.

The Commissioner is hereby authorized to charge any required fees, if necessary, to Deposit No. 50-1108.

Respectfully submitted,

Dated: September 1, 2005

  
\_\_\_\_\_  
Laleh Shayesteh      Reg. No. 47,937  
Tel: (650) 837-8223; Fax: (650) 837-8234



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of Gendreau *et al.*

Application No.: 10/535,443

Filed: May 19, 2005

For: FLJ10607 AS MODIFIER OF THE  
AXIN PATHWAY AND METHODS  
OF USE

Confirmation No.: 8809

Art Unit: Not Assigned

Examiner: Not Assigned

Attorney Docket No.: EX03-098C-US

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The GENESEQ® database was queried to identify sequences that are identical or related to the sequences recited in the claims of the above-referenced patent application. The following patent publications were identified:

WO0164904, MILLENNIUM PHARMACEUTICALS, INC., 2001-09-07  
WO0132888, INCYTE GENOMICS, INC., 2001-05-10  
WO0073801, LUDWIG INSTITUTE FOR CANCER RESEARCH, 2000-12-07  
WO02072757, CURAGEN CORPORATION, 2002-09-19  
WO0164903, LEXICON GENETICS INCORPORATED, 2001-09-07

The above-references have **not** been reviewed to assess whether they are material to the patentability of the claimed invention; nor have they been reviewed to assess whether they are substantively cumulative to the disclosures of the references cited in and provided with the "Information Disclosure Statement by Applicant" filed simultaneously herewith.

Upon request, Applicants will gladly obtain copies of any of these references and forward them to the Examiner for consideration.

Respectfully submitted,

Dated: September 1, 2005

Laleh Shayesteh                      Reg. No. 47,937  
Tel: (650) 837-8223; Fax: (650) 837-8234



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	10/535,443
Filing Date	May 19, 2005
First Named Inventor	Gendreau
Art Unit	
Examiner Name	
Attorney Docket Number	EX03-098C-US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	1	International Human Genome Sequencing Consortium. Homo sapiens glucosamine-phosphate N-acetyltransferase 1 (GNPNAT1), mRNA. GI:18597005 28-APR-2003	
	2	Strausberg, R.L., Homo sapiens glucosamine-phosphate N-acetyltransferase 1, mRNA (cDNA clone MGC:20441 IMAGE:4661046), complete cds. GI:15082537 18-JUL-2005	/
	3	Strausberg, R.L., Homo sapiens glucosamine-phosphate N-acetyltransferase 1 (GNPNAT1), mRNA. GI:37620193 23-DEC-2003	/
	4	International Human Genome Sequencing Consortium. similar to glucosamine-phosphate N-acetyltransferase 1; glucosamine-phosphate N-acetyltransferase; glucosamine-6-phosphate acetyltransferase [Homo sapiens]. GI:18597006 28-APR-2003	/
	5	Ota, T., glucosamine-phosphate N-acetyltransferase 1 [Homo sapiens]. GI:37620194 23-APR-2005	/

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.